Current challenges in the development of new treatments for lupus

Maria Dall'Era, Ian N. Bruce, Caroline Gordon, Susan Manzi, Janis McCaffrey, Peter E. Lipsky

Research output: Contribution to journalComment/debatepeer-review


Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a considerable impact on patients' quality of life. Despite the plethora of clinical trials for SLE since the turn of the millennium, only one new treatment has been approved for the condition, and the overall pace of successful drug development remains slow. Nevertheless, the myriad of clinical studies has yielded insights that have informed and refined our understanding of eligibility criteria, outcome measures and trial design in SLE. In this review, we highlight the achievements of clinical trials as well as the major pitfalls that have been identified in drug development for SLE and, in doing so, identify areas where collaboration and consensus will be important to facilitate progress.

Original languageEnglish
Pages (from-to)729-735
Number of pages7
JournalAnnals of the rheumatic diseases
Issue number6
Publication statusPublished - 1 Jun 2019


  • autoantibodies
  • autoimmune diseases
  • lupus nephritis
  • systemic lupus erythematosus

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute
  • Manchester Institute for Collaborative Research on Ageing


Dive into the research topics of 'Current challenges in the development of new treatments for lupus'. Together they form a unique fingerprint.

Cite this